Paczesny, Mehrotra named co-leaders of cancer immunology at Hollings Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Sophie Paczesny and Shikhar Mehrotra were named co-leaders of the cancer immunology program at Hollings Cancer Center at the Medical University of South Carolina.

Paczesny begins her appointment on July 1 as a professor and chair of the Department of Microbiology and Immunology at MUSC in the College of Medicine. Mehrotra, whose appointment began March 2, is an associate professor in MUSC’s Department of Surgery in the College of Medicine, and is also the co-director of the MUSC Clean Cellular Therapy unit.

Mehrotra has been with Hollings Cancer Center since 2006. His research focuses on understanding T-cell signaling and metabolic pathways to improve the functionality of T cells in adoptive cell therapy.

Paczesny is a member and counselor for the American Society for Clinical Investigation, co-chairperson for both the Center for International Blood and Marrow Transplant immunobiology working group and the American Society of Hematology task force on immunotherapies.

Other areas of her research include developing and translating biomarkers for the outcomes following allogeneic hematopoietic stem cell transplantation (HCT); discovering inhibitors of drug targetable biomarkers for HCT patients; finding novel therapies to treat graft-versus-host disease and improve graft-versus-leukemia reactions, including cellular therapies; and exploring the Alarmin Interleukin-33/ST2 signaling pathway as a novel immune checkpoint in myeloid malignancies and other cancers.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login